Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
Clinical trial NCT06227325 · UNKNOWN
Trial details
- NCT number
- NCT06227325
- Sponsor
- Henan Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-01
- Primary completion
- 2024-12-31
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.